Skip to main content
MedNextMedNext
RheumRheumatology

SLE Disease Activity Index 2000 (SLEDAI-2K)

Measures SLE disease activity across 24 weighted descriptors. Guides treatment intensity and monitors flares. Score >4 indicates active disease.

Seizure — new onset (excluding metabolic, drug, or infectious causes)?
Psychosis — severe perceptual disturbance/altered reality testing?
Organic brain syndrome — altered mental function with disorientation/memory impairment?
Visual disturbance — retinal changes (cytoid bodies, haemorrhage, papilloedema)?
Cranial nerve disorder — new sensorimotor neuropathy involving cranial nerves?
Lupus headache — severe persistent, not responsive to narcotics?
Cerebrovascular accident — new (excluding arteriosclerosis)?
Vasculitis — ulceration/gangrene/tender nodules/splinter haemorrhages/angiogram evidence?
Arthritis — ≥2 joints with pain, tenderness, and signs of inflammation?
Myositis — proximal muscle aching/weakness with elevated CK or EMG changes?
Urinary casts — haeme-granular or red cell casts?
Haematuria — >5 RBC/hpf (excluding calculus, infection)?
Proteinuria — >0.5 g/24h (new or recent increase)?
Pyuria — >5 WBC/hpf (excluding infection)?
New or recurrent inflammatory rash?
New or recurrent abnormal hair loss?
New or recurrent oral or nasal ulcers?
Pleuritis — pleuritic chest pain with rub/effusion/thickening?
Pericarditis — pericardial pain with rub/effusion/ECG changes?
Decreased complement (CH50, C3, or C4 below lab normal)?
Elevated anti-dsDNA binding (above lab reference range)?
Fever >38°C — excluding infectious cause?
Thrombocytopenia — platelets <100 × 10⁹/L (excluding drugs)?
Leucopenia — WBC <3 × 10⁹/L (excluding drugs)?
0
SLEDAI-2K/ 105
Inactive disease
SLEDAI-2K = 0. No active disease descriptors. Continue current management; monitor for flare.

Reference: Gladman D et al. J Rheumatol 2002

Medical Disclaimer: This calculator is a clinical decision support tool for qualified healthcare professionals. It does not replace clinical judgement. Always interpret results in the full clinical context. Reference: Gladman D et al. J Rheumatol 2002.